Top five unique options volume: AMAT EFX NKE AXON GE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Axovant Sciences (AXON) PT Lowered to $9 at Evercore ISI
September 26, 2017 12:07 PM EDTEvercore ISI analyst Josh Schimmer lowered his price target on Axovant Sciences (NASDAQ: AXON) to $9.00 (from $30.00) while maintaining an Outperform rating after MINDSET Trial Fails
... MoreAxovant Sciences (AXON) PT Lowered to $25 at Cowen; Lewy Body Program Remains Focus
September 26, 2017 11:48 AM EDTCowen analyst Ritu Baral lowered his price target on Axovant Sciences (NASDAQ: AXON) to $25.00 (from $30.00) while maintaining an Outperform rating after the company reported the pivotal Ph3 MINDSET trial of intepirdine in Alzheimer's failed to meet its primary endpoint.
Baral notes... More
UPDATE: Piper Jaffray Downgrades Axovant Sciences (AXON) to Neutral
September 26, 2017 10:53 AM EDT(Updated - September 26, 2017 11:02 AM EDT)
(updated to add analyst comment)
Piper Jaffray downgraded Axovant Sciences (NASDAQ: AXON) from Overweight to Neutral with a price target of $9.00 (from $32.00).
Analyst Charles Duncan says the pipeline needs to be rebuild... More
Oppenheimer Downgrades Axovant Sciences (AXON) to Perform
September 26, 2017 10:48 AM EDTOppenheimer downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Perform.
For an analyst ratings summary and ratings history on Axovant Sciences click here. For more ratings news on Axovant Sciences click here.
Shares of Axovant Sciences closed at $24.25 yesterday.
... More